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ABSTRACT
Purpose To identify bioactive equivalent combinatorial compo-
nents (BECCs) in herbal medicines. The exact composition of
effective components in herbal medicines is often elusive due to
the lack of adequate screening methodology. Herein, we propose
a hypothesis that BECCs accounting for the whole efficacy of
original herbal medicines could be discovered from a complex
mixture of constituents.
Methods We developed a bioactive equivalence oriented feed-
back screening method and applied it to discover the BECCs from
an herbal preparation Cardiotonic Pill (CP). The operations in-
clude chemical profiling of CP, followed by an iterative loop of
determining, collecting and evaluating candidate BECCs.
Results A combination of 18 compounds was identified as
BECCs from CP, which accounts for 15.0% (w/w) of original
CP. We have demonstrated that the BECCs were as effective as
CP in cell models and in a rat model of myocardial infarction.
Conclusions This work answers the key question of which are real
bioactive components for CP that have been used in clinic for many
years, and provides a promising approach for discovering BECCs
from herbal medicines. More importantly, the BECCs could be
extended to improve quality control of herbal products and inspire
an herbal medicines based discovery of combinatorial therapeutics.
KEY WORDS bioactive equivalence . Cardiotonic Pill .
combinatorial components screening . herbal medicines
ABBREVIATIONS
BECCs Bioactive equivalent combinatorial components
CCK-8 Cell counting kit-8
CK-MB Creatine kinase-MB
CP Cardiotonic Pill
HUVEC Human umbilical vein endothelial cell
IL-6 Interleukin-6




LVEDP Left ventricular end diastolic pressure
LVSP Left ventricular systolic pressure
MI Myocardial infarction
MRCs Mixture of reference compounds
Ox-LDL Oxidized low density lipoprotein
PGE2 Prostaglandin E2
PLS-DA Partial least square-discriminant analysis
ROS Reactive oxygen species
SD Standard deviation
SI Simulated ischemia
TNF-α Tumor necrosis factor-α
TTC Triphenyltetrazolium chloride
INTRODUCTION
Herbal medicines have played an important role in health
maintenance and disease treatment for thousands of years
(1,2). Accompanying with hot discussions on developing mul-
tidrug therapy for multi-gene diseases, herbal medicines are
receiving increasing attention worldwide because they have long
been postulated as multicomponent therapeutics in clinical
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practice (3–7). Nevertheless, the exact composition of effective
components is often elusive due to the lack of adequate screening
methodology. A variety of research efforts in recent decades have
been focused on isolating and identifying single effective constit-
uents from herbal medicines. However, they disregarded the
combinatorial role and integrative therapeutic effects of multiple
active compounds (8,9). Generally, the therapeutic efficacy of
herbal medicines is achieved by combinatorial components rath-
er than single compound. Hence, it is incumbent upon re-
searchers to elucidate the exact combinatorial composition of
effective components in herbal medicines, if any, accounting for
of the holistic efficacy of herbal medicines.
In this work, we propose a hypothesis that bioactive equiva-
lent combinatorial components (BECCs) accounting for the
whole efficacy of original herbal medicines could be discovered
from a complex mixture of constituents. To explore BECCs
from herbal medicines, we have developed and described herein
a bioactive equivalence oriented feedback screeningmethod, and
applied it to discover the BECCs from an herbal preparation
Cardiotonic Pill (CP, also known as the Compound Danshen
Dripping Pill). CP is a Chinese herbal medicinal preparation in
which Salviae Miltiorrhizae Radix and other two Chinese
medicines, namely Notoginseng Radix and borneolum, were
combined in a fixed ratio using modern techniques of phar-
maceutical preparation. CP has been widely applied clinically
in China to improve cardiac function and coronary circula-
tion for the therapy of angina pectoris (10,11) and has recently
been approved to enter Phase III clinical trials by the FDA
(ClinicalTrials.gov Identifier: NCT01659580). Herein, we
have identified a combination of 18 compounds as BECCs
out of 36 identified components and other unidentified minor
components, which were as effective as CP in cell models and
in a rat model of myocardial infarction (MI). The content of
BECCs accounts for 15.0% (w/w) of original CP, and could
be considered as the “defined labeled amount” of active
component combination for CP.
This work offers evidence-based data to answer the key
question of which are real bioactive components for Cardiotonic
Pill that have been used in clinic for many years. While
the nature of this study refers specifically to Cardiotonic
Pill, we suggest that this screening method is promising
for detecting BECCs for other herbal medicines, and
more importantly, to improve quality control of herbal medi-
cines and inspire an herbal medicines based discovery of
combinatorial therapeutics.
METHODS
Chemical Profiling of CP
To select candidate BECCs from CP, we initially profiled the
chemical constituents of CP. Three batches of CP (Tasly
Pharmaceutical Co., Ltd., Lot: 100824, 110419, 110510)
were obtained from local drug stores (Nanjing, China). Ref-
erence compounds were obtained from the National Institute
for The Control of Pharmaceutical and Biological Products
(Beijing, China) or previously preserved in our laboratory.
The purity of each reference compound was determined to
be higher than 98%. For HPLC-UV/MS analysis, CP
(15 mg, without addition of excipients) was extracted using
75% (v/v) ethanol (3 ml) for 30 min by ultrasonication and
subsequently centrifuged at 13,000 rpm for 10 min. The
supernatant was analyzed on an Agilent 1100 series HPLC
system (Agilent, USA). The separation was performed on an
Agilent Zorbax SB-C18 column (250×4.6 mm, 5 μm) using
the 0.02% formic acid in water (A) and 0.02% formic acid in
ACN (B). The gradient elution program was 10–22% B at 0–
10 min, 22–23% B at 10–18 min, 23–24% B at 18–23 min,
24–27%B at 23–33min, 27–33%B at 33–40min, 33–41%B
at 40–52 min, 41–70% B at 52–54 min, 70–72% B at 54–
62 min, 72–100% B at 62–70 min, 100% B at 70–77 min.
The flow rate was kept at 0.5 ml/min at 30°C. For segmental
monitoring (12) based on UV, different detection wavelengths
were performed for different periods of time: 203 nm for 0–
57 min; 281 nm for 57–77 min. MS spectra were acquired on
a 6530 Q-TOF mass spectrometer (Agilent, USA) equipped
with an electrospray ionization (ESI) interface. The operating
parameters were as follows: drying gas (N2) flow rate, 10.0 L/
min; drying gas temperature, 320°C; nebulizer, 45 psig; cap-
illary, 3,500 V; skimmer, 65 V; OCT RFV, 750 V; and
fragmentor voltage 120 V. For MS/MS experiments, the
collision energy was adjusted from 15 to 70 V to optimize
signals and obtain maximal structural information from the
ions of interest. The sample was analyzed in both positive and
negative modes. The mass range was set at m/z 100–3,000.
Trapping and Preparing Candidate BECCs
To obtain the combination of candidate BECCs, we applied
the real-time components trapping and combining system for
sample preparation (Figure S1, Supplementary Material).
A preparative Agilent 1100 series HPLC system was
coupled to a LEAP Shell fraction collection system
(LEAP Technologies, USA). The fraction collection sys-
tem was composed of an autosampler (HTC PAL MXY
04-01A), a system control software (LEAP Shell 3) and
a fraction collector (HTC PAL MXY 013-02A). The
HPLC separation was performed on an Agilent Zorbax
SB-C18 semi-preparative column (250×9.4 mm, 5 μm) with
a flow rate of 2 ml/min, and other HPLC conditions were the
same as those in chemical profiling of CP.
After the injection of 20 μl CP at the concentration of
100 mg/ml in 75% (v/v) ethanol, candidate BECCs were
prepared using the real-time components trapping and com-
bining system (Figure S1, Supplementary Material) according
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to the collection program as following: P2 at 648–690 s, P3 at
996–1,050 s, P5 at 1,308–1,380 s, P6 at 1,386–1,446 s, P7 at
1,548–1,620 s, P8–P9 at 1,866–1,992 s, P10 at 2,001–2,052 s,
S3 at 2,058–2,130 s, P11 at 2,256–2,382 s, P12 at 2,640–
2,772 s, S5 at 3,060–3,102 s, S9 at 3,312–3,348 s, S12 at
3,402–3,438 s, T3 at 4,110–4,146 s, T4–T5 at 4,356–4,440 s,
T7 at 4,560–4,602 s. Candidate BECCs were collected at
position II while the remaining part was collected at position
I. Subsequently, the solvent was removed using a speedvac
evaporator (Genevac EZ-2 plus, Genevac Technologies, UK).
The samples were reconstituted at a concentration as in
original CP for method validation and bioactivity assay.
Bioactivity Assays In Vitro
To assess the bioactive equivalence, we evaluated the bioac-
tivities of candidate BECCs and the original CP simultaneous-
ly. Three cell models related to angina pectoris were used
(13,14), including oxidized low density lipoprotein (Ox-LDL)-
mediated human umbilical vein endothelial cell (HUVEC)
injury (15), lipopolysaccharide (LPS)-stimulated RAW 264.7
macrophage inflammation (16), and simulated ischemia (SI)-
induced H9c2 cardiomyocytes injury (17). If the 90% confi-
dence interval (CI) of relative efficacy compared to original
CP fell within the range of 70–143% (18), the candidate
BECCs were considered to be a bioactive equivalent with
original CP.
HUVEC (EA.hy926), mouse macrophage (RAW 264.7)
and rat cardiomyoblast (H9c2) cell lines were purchased from
American Type Culture Collection (ATCC, USA). Cells were
grown at 37°C under a humidified atmosphere with 5% (v/v)
CO2 in accordance to optimal media and growth conditions
specified by ATCC.
To assess the effect of candidate BECCs on HUVECs, we
pretreated cells with various samples (corresponding concen-
trations in 0.4 mg/ml Cardiotonic Pill) or Trolox (100 μM, as
a positive control) for 12 h. After preincubation, supernatant
was removed and cells were subjected to Ox-LDL (70 μg/ml,
XieSheng Biotechnology, China) for 24 h except the vehicle
control group. Cell viability was determined by cell counting
kit-8 (CCK-8, Dojindo Molecular Technologies Inc., Japan).
Supernatant was collected for lactate dehydrogenase (LDH)
assay (Jiancheng Bioengineering Institute, China) according to
the manufacturer’s instructions. ROS production in
HUVECs was determined by a fluorometric assay using
DCFH-DA (Beyotime, China) as previously reported (19).
To assess the anti-inflammatory effect of candidate
BECCs, themacrophages were pretreated for 2 h with various
samples (corresponding concentrations in 0.5 mg/ml Cardio-
tonic Pill) or luteolin (20 μM, as a positive control) and then
stimulated for 20 h with LPS (1 μg/ml). The NO production
was determined as nitrite concentration in the culture medium
according to a Griess reaction (20). The accumulated
interleukin-6 (IL-6) and prostaglandin E2 (PGE2) in the cul-
ture medium were measured using commercial ELISA kits
(R&D, USA) according to the manufacturer’s instructions.
To evaluate the protective effect of candidate BECCs on
cardiomyocytes against simulated ischemia injury, a rat H9c2
cardiomyoblasts simulated ischemia model was established
(17). After overnight incubation, the cells were pretreated for
24 h with various samples (corresponding concentrations in
0.1 mg/ml Cardiotonic Pill). Tomimic the in vivo conditions of
myocardial ischemia, the cells were incubated in a buffer
containing 116.4 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2,
0.8 mM MgSO4, 2.6 mM NaH2PO4, 26.2 mM NaHCO3,
20.l mM HEPES and then exposed to 2% O2−93% N2−5%
CO2 for 6 h. After the treatment, cell viability was determined
by CCK-8 assay (Dojindo Molecular Technologies Inc., Ja-
pan), according to the manufacturer’s instructions. Cells cul-
tured in complete medium under a normoxic atmosphere
served as a control. The treatment concentrations were cho-
sen based on the optimal concentration of Cardiotonic Pill
(Figure S2, Supplementary Material).
Bioactivity Assays In Vivo
To further investigate whether the candidate BECCs (III) are
a bioactive equivalent with original formulation in terms of
in vivo efficacy, we utilized a rat model of MI (21–24). All
animal procedures were approved by the Animal Ethics Com-
mittee of China Pharmaceutical University. Male Sprague-
Dawley rats (250–300 g) were purchased from the Aier Maite
Technology Corporation (Suzhou, China). The rats were
housed in humidity- and temperature- controlled environ-
ment with a 12 h light: 12 h dark cycle. Water and standard
laboratory diet were available ad libitum.
MI was produced by the ligation of the left anterior de-
scending (LAD) coronary artery as reported previously
(21,22). Rats were randomly assigned into seven groups: four
treatment groups (CP, candidate BECCs (III), mixture of
reference compounds (MRCs) (III), remaining part (III)), a
MI group, and a sham group. Briefly, various samples (corre-
sponding concentrations in 20 mg/kg Cardiotonic Pill) in the
treatment group were given once daily by oral administration
for 3 days before MI. The sham and MI group received only
saline. For MI operation, rats were anesthetized with chloral
hydrate (300 mg/kg i.p.) and ventilated by a respirator (HX-
100E, Taimeng Co. Ltd., China) with a tidal volume of
10 ml/kg and a respiratory rate of 80 cycles per minute. A
left thoracotomy was performed in the fourth intercostal
space, and thenMI was induced by ligation of the LAD artery
2 mm from the tip of the left auricle. The sham-operated rats
underwent the same thoracotomy without LAD ligation. Elec-
trocardiogram was recorded before and after operation pro-
cedures. Coronary occlusion was confirmed by ST segment
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elevation in the electrocardiogram and the appearance of
epicardial cyanosis.
To evaluate the bioactivity of candidate BECCs (III) on
cardiac function, left ventricular (LV) catheterization was
performed (25). At the end of 6 h ischemic period, a catheter
was inserted into the left ventricle for evaluating cardiac
function. Left ventricular end diastolic pressure (LVEDP), left
ventricular systolic pressure (LVSP), +dP/dt and -dP/dt were
recorded through a biological mechanic experiment system
(BL420, Taimeng Co. Ltd., China). Cardiac marker enzymes
including creatine kinase-MB (CK-MB) and LDHwere tested
for estimation of myocardial cell damage using commercial
kits (Jiancheng Bioengineering Institute, China) (26). To in-
vestigate the bioactivity of candidate BECCs (III) on inflam-
matory response, tumor necrosis factor-α (TNF-α) level in
serum was measured using a commercial ELISA kit (R&D,
USA) (27). At the end of experiment, the heart was excised,
sliced into five sections, and infarct size was measured using 2,
3, 5-triphenyltetrazolium chloride (TTC) staining to assess
myocardial injury as reported previously (28,29). Sections
were photographed and the area at risk was quantified with
the aid of the Image-Pro Plus 6 software.
Metabolomic Profiling
To validate the assessment results of bioactive equivalence
between BECCs and original CP, metabolomics strategy
was applied to profile the metabolites in rat myocardial tissues
using gas chromatography/time-of-flight mass spectrometry
(GC/TOF MS) coupled to partial least square-discriminant
analysis (PLS-DA). Rat hearts (n=4–6) were immediately
snap-frozen in liquid nitrogen and stored at −80°C until
metabolomic profiling. The same extraction, derivatization,
and analysis procedures were applied as described previously
(30,31). Myocardial tissue (20 mg) from infart area was ho-
mogenized in a tube containing 800 μl methanol. [1, 2-13C2]
Myristic acid was added to each tube as the internal standard.
With an Agilent 7683 autosampler, the derivatized samples
were analyzed using an Agilent 6890N GC system (Agilent,
USA) coupled with a Pegasus III mass spectrometer (Leco,
USA). The injector temperature was set at 270°C and helium
was used as carrier gas at a constant flow rate of 1 ml/min.
Column temperature was initially maintained at 70°C for
2 min and then was increased at a rate of 35°C/min to
305°C, where it was held for 2 min. The transfer line temper-
ature was set at 250°C and ion source temperature at 200°C
for themass spectrometer. A 70-eV electron beam at a current
of 2.0 mA were used for ions generation. The GC/TOF MS
data of metabolites profiling of myocardial tissue were
analyzed by PLS-DA, using the SIMCA-P 11.0 (Umetrics,
Sweden). For PLS-DA modeling, samples were divided into
different groups (e.g., sham, MI, BECCs and CP) as the
qualitative “dummy” variable, Y.
Statistical Analysis
All bioactive data were presented as mean ± standard devia-
tion (SD). Data were subjected to statistical analysis using
Graphpad Prism 6.0. One-way analysis of variance
(ANOVA) with Dunnett’s post-hoc test was carried out for
statistical comparison. In all cases, a P-value<0.05 was con-
sidered to be significant.
For bioactive equivalence assessment, all the bioassay re-
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where Activitydrug, Activitymodel and Activitycontrolwere the measured
values of drug group (candidate BECCs, MRCs or original
CP treated), model group (Ox-LDL-mediated HUVEC inju-
ry, LPS-stimulated RAW 264.7 macrophage inflammation,
simulated ischemia-induced H9c2 cardiomyocytes injury or
myocardial infarction) and control group respectively in a
given bioassay. Bioactive equivalence was evaluated by calcu-
lating 90% confidence interval (CI) of the ratio between the
efficacies of candidate BECCs and CP (two one-sided t test,
see more information in Supplementary Material). If the 90%
CI of relative efficacy compared to original CP fell within the
range of 70–143% (18), the candidate BECCs were consid-
ered to be a bioactive equivalent with original CP.
RESULTS
Chemical Profiling of CP
A variety of components were detected at HPLC-UV chro-
matogram using the segmental monitoring method (Fig. 1a).
Structural characterization was performed by Q-TOF MS,
and the total ion chromatograms of CP in positive and nega-
tive ion modes were shown in Figure S3, Supplementary
Material. In total, 36 compounds in CP were detected and
identified by comparison with available reference compounds
or literature information, including 13 phenolic acids, 15
saponins and 8 tanshinones (Table I) (32,33).
Determination of Candidate BECCs from CP
In our experiment, normalized peak area ratio (%) was chosen as
the selection criterion. According to theHPLC chromatogram of
CP, the selection threshold was set at 10% of the total peak area
in the first round and only one peak, identified as tanshinol, was
trapped and prepared, labeled as candidate BECCs (I) (Fig. 1b).
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When the selection threshold was reduced to 1% or 0.1%, 10 or
18 peaks were prepared as candidate BECCs (II) or candidate
BECCs (III), respectively (Fig. 1c and d). Candidate BECCs (II)
mainly consisted of phenolic acids, while candidate BECCs (III)
consisted of 10 phenolic acids, 4 saponins and 4 tanshinones.
Remaining part (III) of CP without candidate BECCs (III)
mainly consisted of highly polar compounds such as carbohy-
drates, and other minor constituents.
Trapping and Preparing Candidate BECCs
Three batches of candidate BECCs based on the described
selection threshold were prepared through the corresponding
collection programs. Using a semi-preparative column, the
system could provide samples at the milligram level per HPLC
run, which was adequate for cell tests. For our experiments in
rats, a 1 week preparation period was required to accumulate
Fig. 1 Validation of candidate BECCs in the three rounds of screening by HPLC-UV. Samples of Cardiotonic Pill (depicted in green), candidate BECCs (red) and the
remaining part (blue) were analyzed at the same concentration. UV wavelengths: 203 nm for 0–57 min; 281 nm for 57–77 min. The peaks in the chromatograms are
assigned the same numbers as in Figure S3, Supplementary Material. (a) Chromatogram of Cardiotonic Pill. (b) Chromatogram of candidate BECCs (I) and remaining part
(I). Candidate BECCs (I) consisted of one compound, identified as tanshinol. (c) Chromatogram of candidate BECCs (II) and remaining part (II). Candidate BECCs (II)
consisted of 10 compounds (mainly phenolic acids). (d) Chromatogramof candidate BECCs (III) and remaining part (III). Candidate BECCs (III) consisted of 18 compounds,
including 10 phenolic acids, 4 saponins and 4 tanshinones. BECCs bioactive equivalent combinatorial components.
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sufficient samples using this system. The prepared samples were
dried and reconstituted with 75% (v/v) ethanol to the original
concentration for HPLC validation. As shown in Fig. 1, candi-
date BECCs were trapped and prepared from CP completely.
The preparation process may potentially lead to sample
loss because of possible adsorption to the chromatographic
column and compound degradation during heating processes.
Thus, we investigated the preparative recovery and repeat-
ability for each compound in the candidate BECCs (Table S1,
Supplementary Material). The preparative recovery ranged
from 87.7% to 97.9%, while the average recovery rate was
approximately 92.9%. The preparative process showed stable
repeatability with a RSD<6.6%. This result indicates that the
described system is feasible and reliable.
In VitroAssessment of Bioactive Equivalence
Between Candidate BECCs and Original CP
CP showed remarkable protective effects in the three cell
models, while candidate BECCs (I) exerted weak effects
Table I The Retention Time, MS Data and Characterization of Identified Phenolic Acids, Saponins and Tanshinones in Cardiotonic Pill
Peak no. tR (min) [M-H]
−(m/z) Theoretical (m/z) Error (ppm) Formula Identification
P1 8.85 197.0450 197.0455 −2.77 C9H10O5 (s)-3-(3,4-dihydroxyphenyl) lactic acid
P2a 9.76 197.0453 197.0455 −1.25 C9H10O5 Tanshinol
P3a 15.38 137.0246 137.0244 1.33 C7H6O3 Protocatechuic aldehyde
P4a 16.60 179.0351 179.0350 0.66 C9H8O4 Caffeic acid
P5a 20.70 537.1032 537.1038 1.12 C27H22O12 Isolithospermic acid A
P6a 21.89 537.1041 537.1038 −0.34 C27H22O12 Isolithospermic acid B
P7a 24.73 417.0830 417.0827 0.67 C20H18O10 Salvianolic acid D
P8a 29.40 339.0518 339.0510 2.28 C18H12O7 Salvianolic acid G
P9a 30.30 359.0780 359.0772 2.11 C18H16O8 Rosmarinic acid
P10a 30.67 537.1045 537.1038 1.58 C27H22O12 Lithospermic acid
S1a 31.04 977.5309 977.5327 1.62 C47H80O18 Notoginsenoside-R1
S2a 33.82 991.5497 991.5483 −1.47 C48H82O18 Ginsenoside-Re
S3a 34.15 845.4912 845.4904 −1.09 C42H72O14 Ginsenoside-Rg1
P11a 34.91 717.1461 717.1465 −0.55 C36H30O16 Salvianolic acid B
P12a 41.63 493.1146 493.1140 −1.21 C26H22O10 Salvianolic acid A
P13a 46.67 491.0990 491.0984 1.28 C26H20O10 Salvianolic acid C
S4a 50.10 845.4899 845.4904 −0.01 C42H72O14 Ginsenoside-Rf
S5a 52.13 1,153.6005 1,153.6011 1.04 C54H92O23 Ginsenoside-Rb1
S6a 52.76 815.4792 815.4798 1.12 C41H70O13 Notoginsenoside-R2
S7a 53.63 829.4951 829.4955 0.48 C42H72O13 Ginsenoside-Rg2
S8 54.43 1,123.5878 1,123.5906 2.61 C53H90O22 Ginsenoside-Rb3
S9a 55.15 683.4379 683.4376 −0.56 C36H62O9 Ginsenoside-Rh1
S10a 55.56 1,123.5907 1,123.5906 −1.31 C53H90O22 Ginsenoside-Rb2
S11a 56.07 683.4370 683.4376 0.98 C36H62O9 Ginsenoside-F1
S12a 57.21 991.5507 991.5483 −2.39 C48H82O18 Ginsenoside-Rd
S13a 59.76 829.4959 829.4955 −0.20 C42H72O13 Ginsenoside-F2
S14a 60.45 829.4963 829.4955 −0.88 C42H72O13 20(S)-Ginsenoside Rg3
S15a 60.78 829.4936 829.4955 2.18 C42H72O13 20(R)-Ginsenoside Rg3
T1a 62.10 311.1288 311.1278 2.84 C19H18O4 Tanshinone IIB
T2 63.61 337.1429 337.1434 1.70 C21H20O4 Danshenxinkun D
T3a 66.81 279.1021 279.1016 1.86 C18H14O3 15,16-Dihydrotanshinone I
T4a 71.01 277.0864 277.0859 2.96 C18H12O3 Tanshinone I
T5a 71.55 297.1496 297.1485 2.75 C19H20O3 Cryptotanshinone
T6a 72.92 279.1023 279.1016 −2.56 C18H14O3 Methylenetanshinquinone
T7a 74.48 295.1334 295.1329 1.77 C19H18O3 Tanshinone IIA
T8a 75.01 283.1704 283.1693 −4.07 C19H22O2 Miltirone
P1–P13 phenolic acids; S1–S15 saponins; T1–T8 tanshinones. tR: retention time
a Compared with reference compounds
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(Fig. 2a) and could not achieve bioactive equivalence as com-
pared to the original CP (Table II). As such, we adjusted our
feedback loop by reducing the selection threshold to 1% of
total peak area and performed the second round of screening.
Candidate BECCs (II) comprised of 10 compounds showed
some activities (Fig. 2b). However, in the bioactive equiva-
lence assessment, candidate BECCs (II) failed to meet the 70–
143% requirements (Table II). For example, we observed a
notable anti-inflammatory effect of candidate BECCs (II) in
macrophages compared with model group (Fig. 2b,
P<0.0001, n=3, one-way ANOVA, Dunnett test), but 90%
CI of efficacy in suppressing the production of nitric oxide
(NO) was 49.0–56.0%, and demonstrated that candidate
BECCs (II) could not achieve bioactive equivalence with
CP. In the third round of screening, the selection threshold
was further reduced to 0.1% of total peak area, candidate
BECCs (III) of 18 compounds increased the cell viability of
damaged HUVECs and cardiomyocytes, and also alleviated
the LPS-induced increase of NO in macrophages compared
with model group (Fig. 2c, in HUVECs, P<0.0001; in mac-
rophages, P<0.0001; in cardiomyocytes, P<0.0001, n=3,
one-way ANOVA, Dunnett test). In the bioactive equivalence
assessment, 90%CI for the efficacies of candidate BECCs (III)
in all the cell tests fell within 70–143%, as listed in Table II. At
the same time, the low activity of remaining part (III) also
suggested that most of the bioactive components of CP were
included in candidate BECCs (III).
Ox-LDL increased LDH release and reactive oxygen spe-
cies (ROS) concentration in HUVECs substantially, whereas
preincubation with CP or candidate BECCs (III) notably
Fig. 2 In vitroactivity assays of candidate BECCs in the three rounds of screening. Samples in (a) the first round of screening, (b) the second round of screening, (c)
the third round of screening were investigated in three cell models. HUVEC injury was induced by incubation with Ox-LDL and cell viability (as % of control) was
assayed by CCK-8. Effects of samples on NO production of LPS-activated murine macrophage RAW264.7 cells was determined by Griess reaction. After 6 h of
simulated ischemia, cell viability of H9c2 cardiomyoblasts was assayed by CCK-8. Trolox and luteolin were used as a positive control in HUVECs and
macrophages respectively. Results are expressed as mean ± SD of at least three independent experiments. *P<0.05, **P<0.01 versus model group. ##
P<0.01 versus vehicle control group (one-way ANOVA, Dunnett test). Cells in model group were untreated. CPCardiotonic Pill; BECCs bioactive equivalent
combinatorial components;MRCsmixture of reference compounds; Remaining part: CP lacking candidate BECCs; Ox-LDLoxidized low density lipoprotein; LPS
lipopolysaccharide; SI simulated ischemia.
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attenuated the Ox-LDL-induced damage (Fig. 3a, CP versus
Ox-LDL group, P<0.0001 for LDH assay, P<0.0001 for ROS
assay; candidate BECCs (III) versus Ox-LDL group, P<0.0001
for LDH assay, P<0.0001 for ROS assay, n=3, one-way
ANOVA, Dunnett test). Additionally, results were consistent
with the cell viability assay (Fig. 2c). To investigate the biolog-
ical activities on macrophages, LPS stimulation resulted in a
substantial increase of IL-6 and PGE2 secretion, while pre-
incubation of CP or candidate BECCs (III) alleviated the
LPS-induced increase of these inflammatory factors (Fig. 3b,
CP versus LPS group, P<0.0001 for IL-6 assay, P<0.0001 for
PGE2 assay; candidate BECCs (III) versus LPS group,
P<0.0001 for IL-6 assay, P<0.0001 for PGE2 assay, n=3,
one-way ANOVA, Dunnett test). The results suggested that
candidate BECCs (III) had a similar efficacy to CP.
In the bioactive equivalence assessment, 90% CI showed
that ratios of efficacies between CP and candidate BECCs (III)
in most cases lay within the acceptance range of 70-143%
(Table II). Thus, candidate BECCs (III) could be considered
as BECCs of CP in vitro.
To exclude the contribution of any undetected peaks
masked in the candidate BECCs collected, we prepared a
Table II Bioactive Equivalence Evaluation of Candidate BECCs and MRCs by In Vitro Assays
In vitro assay Candidate BECCs (I) MRCs (I) Candidate BECCs (II) MRCs (II) Candidate BECCs (III) MRCs (III)
HUVECs
Cell viability 2.1–13.2% 1.5–23.6% 20.7–58.8% 23.7–44.8% 77.0–100.4% 77.8–107.7%
LDH – – – – 79.6–93.6% 73.5–91.1%
ROS – – – – 78.6–85.1% 73.7–79.0%
Macrophages
NO 10.5–18.0% 8.4–13.0% 49.0–56.0% 53.1–63.1% 80.6–92.3% 91.8–100.4%
IL-6 – – – – 81.7–84.1% 78.6–81.0%
PGE2 – – – – 120.1–150.0% 147.1–185.3%
Cardiomyocytes
Cell viability 38.3–47.8% 13.7–52.1% 22.5–27.3% 8.2–23.0% 75.6–105.9% 77.3–104.8%
n=3. Bioactive equivalence was evaluated by two one-sided t test. The 90% CI of relative efficacy of candidate BECCs and MRCs compared to original CP was
showd in the table. If the 90% CI of relative efficacy fell within the range of 70–143%, the candidate BECCs were considered to be a bioactive equivalent with
original Cardiotonic Pill
BECCs bioactive equivalent combinatorial components; MRCsmixture of reference compounds
Fig. 3 Effects of Candidate BECCs (III) on LDH and ROS in HUVECs and IL-6 and PGE2 in macrophages. (a) HUVECs were incubated with vehicle, CP, candidate
BECCs (III), MRCs (III), remaining part (III) and trolox for 12 h, following 24-h stimulation of Ox-LDL. Supernatant of HUVECs was collected for LDH assay by a
commercial kit. ROS production (as % of increase) in HUVECs was determined by a fluorometric assay using DCFH-DA as a probe. (b) Macrophages were pretreated
with vehicle, CP, candidate BECCs (III), MRCs (III), remaining part (III) and luteolin for 2 h, following 20-h stimulation of LPS. The accumulated IL-6 and PGE2 in the culture
mediumweremeasured using commercial ELISA kits. Trolox and luteolin were used as a positive control in HUVECs andmacrophages respectively. Results are expressed
as mean ± SD of at least three independent experiments. *P<0.05, **P<0.01 versus model group. ## P<0.01 versus vehicle control group (one-way ANOVA,
Dunnett test). Cells in model group were untreated. CPCardiotonic Pill; BECCsbioactive equivalent combinatorial components;MRCsmixture of reference compounds;
Remaining part: CP lacking candidate BECCs; Ox-LDL oxidized low density lipoprotein; LPS lipopolysaccharide.
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mixture of reference compounds (MRCs) with the identical
compositions of candidate BECCs (Table S2, Supplementary
Material) for bioactivity validation. Similar with candidate
BECCs (III), MRCs (III) showed marked protective effects in
all three cell models (Figs. 2c and 3). The bioactive equiva-
lence assessment data were also consistent with that of candi-
date BECCs (III); 90%CI of efficacies inmost cases forMRCs
(III) lay within 70–143% (Table II).
When the 18 compounds in candidate BECCs (III) were
given individually at the concentration as in the original CP,
none of these compounds showed substantial protective effects
on HUVECs (Fig. 4a). For example, tanshinol, one of the
most abundant compounds in CP, demonstrated weak pro-
tective effects on HUVECs at the same dose level as in the
formulation (10.7 μg/ml). When the dose increased to
40 μg/ml, tanshinol showed some activity on HUVECs
(Fig. 4b, tanshinol versus Ox-LDL group, P=0.0027, n=3,
one-way ANOVA, Dunnett test), but it was not able to
achieve bioactive equivalence with CP, even up to
100 μg/ml. Candidate BECCs (III) consisted of three groups
of ingredients, including 10 phenolic acids, 4 saponins and 4
tanshinones. In order to test whether each group of
constituents is necessary, phenolic acids, saponins or
tanshinones were removed from candidate BECCs (III) re-
spectively, and the combination of any two groups could not
show equivalent bioactivity to original CP (Figure S4, Sup-
plementaryMaterial). The results indicated that each group of
ingredients was indispensable.
In VivoAssessment of Bioactive Equivalence
Between Candidate BECCs and Original CP
TTC-stained hearts were shown in Fig. 5a. Pretreatment with
CP significantly reduced the infarct size compared with the
MI group (Fig. 5b, 29.4±4.0% versus 53.3±3.7%, P=
0.0016, n=5, one-way ANOVA, Dunnett test). Candidate
BECCs (III) showed a similar effect of decreasing the infarct
size to 29.4±3.0% (Fig. 5b, P=0.0016, n=5, one-way
ANOVA, Dunnett test). MI resulted in marked elevation in
the serum levels of CK-MB and LDH (Fig. 5c and d). CP and
candidate BECCs (III) inhibited the MI-induced increases in
the activities of these enzymes (Fig. 5b, CP versus MI group,
P=0.0004 for CK-MB assay, P=0.0017 for LDH assay; can-
didate BECCs (III) versus MI group, P<0.0001 for CK-MB
Fig. 4 Protective effects of
compounds in BECCs on HUVECs
against Ox-LDL injury. HUVEC
injury was induced by pretreatment
with Ox-LDL for 24 h and cell
viability (as % of control) was
assayed by CCK-8. (a) Protective
effects of 18 individual compounds.
The concentrations of 18
compounds were equal to their
concentrations in 0.4 mg/ml
Cardiotonic Pill. Compound P2 is
tanshinol with a concentration of
10.7 μg/ml (marked in red). (b)
Protective effects of tanshinol on
HUVECs at different doses. Results
are expressed as mean ± SD of at
least three independent
experiments. **P<0.01 versus
Ox-LDL group. ## P<0.01
versus vehicle control group (one-
way ANOVA, Dunnett test). Cells
in model group were untreated.
BECCs bioactive equivalent
combinatorial components; CP
Cardiotonic Pill; Ox-LDL oxidized
low density lipoprotein.
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assay, P<0.0001 for LDH assay, n=8, one-way ANOVA,
Dunnett test). These results indicate that the cardio-
protective effect of candidate BECCs (III) is comparable to
that of CP in vivo.
MI resulted in a substantial increase of TNF-α, while pre-
incubation of CP or candidate BECCs (III) attenuated the
elevation of TNF-α level (Fig. 5e, CP versus MI group,
P<0.0001; candidate BECCs (III) versus MI group,
P<0.0001, n=8, one-way ANOVA, Dunnett test). Compared
with the sham group, LVEDP was increased while LVSP,
maximal rate of increase of LV pressure (+dP/dt) and maximal
rate of decrease of LV pressure (-dP/dt) were decreased post-
MI (Fig. 5f and g). Treatment with candidate BECCs (III)
exhibited significant improvements on the heart’s diastolic
and systolic functions (Fig. 5f and g).
According to the bioactive equivalence assessment,
candidate BECCs (III) suggested comparable efficacy
with original CP within 90% CI (Table III). The low
activity of remaining part (III) also indicated that most
of the bioactive components of CP were included in
candidate BECCs (III) (Fig. 5). Furthermore, MRCs
(III) containing the same constituents as candidate
Fig. 5 Candidate BECCs (III) showed comparable cardio-protective effects with CP against myocardial infarction. (a) Representative pictures of 2, 3, 5-
triphenyltetrazolium chloride-stained myocardial sections (scale bar, 0.5 cm). Red arrow indicates non-infarct region while white arrow indicates infarct region. n=5.
(b) Quantification of infarct size of different samples. n=5. (c) CK-MB, (d) LDH and (e) TNF-α levels of different samples were determined by commercial kits. n=
8. Left ventricular function including (f) LVEDP, LVSP and (g)+dP/dt, -dP/dt. Results are expressed as mean ± SD, n=8. *P<0.05, **P<0.01 versus MI group.
## P<0.01 versus sham group (one-way ANOVA, Dunnett test). ShamSham operated;MImyocardial infarction; CPCardiotonic Pill; BECCsbioactive equivalent
combinatorial components; MRCsmixture of reference compounds; Remaining part: CP lacking candidate BECCs.
Bioactive Equivalent Combinatorial Components 1797
BECCs (III) (Table S2, Supplementary Material) showed
marked protective effects against MI (Fig. 5). Bioactive
equivalence data were also consistent with that of can-
didate BECCs (III) (Table III).
The results of metabolomic profiling were given as PLS-
DA score plot that represents the metabolomics similarities of
the samples (Fig. S5). The score plot of PLS-DA showed that
both BECCs- and CP-treated groups were close to the sham
group. It was demonstrated that the therapeutic efficacy of
candidate BECCs (III) against MI is comparable to that of
original CP.
DISCUSSION
Natural products and herbal medicines have played an im-
portant role in human health care and treatment of diseases
for thousands of years (1,2). Herbal medicines contain com-
plex and relatively unrefined mixtures of compounds, the
holistic efficacy of herbal medicines is usually a product of
the unresolved integrative effects between the constituents
(3–7). It is not surprising that the previous efforts in isolating
and screening single compounds from herbal medicines are
less satisfactory as expected because any single compound
cannot stand for the whole therapeutic efficacies of herbal
medicines. Thus scientific studies should examine the effect
of multiple constituents taken together rather than testing
single compounds one at a time. It is believed that not all
the components contribute to the efficacy of herbal medicines,
and some constituents contribute largely to the effects. We
assumed that the exact composition of combinatorial compo-
nents accounting for the whole efficacy of original herbal
medicines can be refined from the complex mixtures, and
defined as bioactive equivalent combinatorial components
(BECCs).
To discover BECCs from herbal medicines of interest, we
have established a feedback screening method, as illustrated in
Fig. 6. The operations include chemical profiling of herbal
medicines, followed by an iterative loop of determining,
collecting and evaluating candidate BECCs.
To profile the chemical constituents in complex herbal
medicines, diverse chromatographic methods can be used,
such as high-performance liquid chromatography (HPLC)
coupled with ultraviolet detection (UV), evaporative light
Table III Bioactive Equivalence Evaluation of Candidate BECCs (III) and
MRCs (III) in a Rat Model of Myocardial Infarction
In vivo assay Candidate BECCs (III) MRCs (III)








n=5–8. Bioactive equivalence was evaluated by two one-sided t test. The
90% CI of relative efficacy of candidate BECCs (III) and MRCs (III) compared
to original CP was showd in the table. If the 90% CI of relative efficacy fell
within the range of 70–143%, the candidate BECCs were considered to be a
bioactive equivalent with original Cardiotonic Pill
BECCs bioactive equivalent combinatorial components; MRCs mixture of
reference compounds
Fig. 6 A schematic illustration of bioactive equivalence oriented feedback screening method. The operations include chemical profiling of herbal medicines,
followed by an iterative loop of determining, collecting and evaluating candidate BECCs. (a) Herbal medicines of interest are chemically profiled. (b) Candidate
BECCs are determined from original herbal medicines according to a predefined selection criterion. (c) Candidate BECCs are trapped and prepared, the
remaining part is obtained at the same time. (d) Evaluate the bioactivity of candidate BECCs and assess bioactive equivalence between candidate BECCs and
original herbal medicines. If not bioactive equivalent, candidate BECCswill be reselected until they achieve bioactive equivalence with original herbal medicines. (e)
The BECCs are identified which can account for the whole therapeutic efficacy of original herbal medicines. BECCsbioactive equivalent combinatorial components.
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scattering detector (ELSD) or mass spectrometry (MS). Fur-
thermore, quadrupole time-of-flight mass spectrometry (Q-
TOF MS) followed by database searching can provide struc-
tural information for unknown components.
The next step of the screening method is to determine
which components in herbal medicines as temporally separat-
ed by liquid chromatography are candidates for inclusion in
BECCs. In general, selection criteria for candidate BECCs
are flexible. While normalized peak area ratio (%) was chosen
as the selection criterion in this work, identified chemical
structure, chemical polarity, or binding affinity to bioactive
macromolecules can all be considered as reference parameters
(34–36). Indeed, any components of interest or their combi-
nations can be selected and evaluated.
To obtain a combination of candidate BECCs based on a
predefined criterion, we engineered a real-time components
trapping and combining system (Figure S1, Supplementary
Material). Candidate BECCs and the remaining parts of
herbal medicines can be prepared at the same time and used
for bioactivity evaluation. Importantly, the concentration and
proportion of constituents in candidate BECCs remained the
same as that in original herbal medicines for bioactivity assay.
Because the preparation process may potentially lead to sam-
ple loss, the investigation of the preparative recovery and
repeatability for candidate BECCs is essential to ensure the
feasibility and reliability of the preparation system.
To address the issue of comparing efficacy of the candidate
BECCs with the original herbal medicines, we propose a
concept of bioactive equivalence that is similar to bioequiva-
lence in pharmacokinetics (37). Candidate BECCs are con-
sidered to be bioactive equivalents with original herbal med-
icines if the ratio of their efficacies falls within an acceptable
range for a given assay. In this study, the efficacies of candi-
date BECCs and original CP were evaluated in three cell
models and a rat model of MI. According to the efficacy
assessment, selection criteria were stepwise adjusted until the
candidate BECCs could achieve bioactive equivalence with
original herbal medicines.
A combination of 18 compounds was identified as BECCs
from CP using the bioactive equivalence oriented feedback
screening method. We suggest that the developed screening
method and the discovered BECCs can be applied for the
selection of chemical markers for quality control of herbal
medicines. Chemical markers are key to ensure the efficacy,
safety and batch-to-batch consistency of herbal medicines. In
most cases, due to insufficient chemical and pharmacological
data for herbal medicines, lack of evidence-based chemical
markers remains a major challenge for the quality control of
herbal medicines (38,39). Using the described bioactive equiv-
alence oriented feedback screening method, we can assess the
rationality of designed chemical markers involved in Pharma-
copeias and may suggest more suitable chemical markers. It is
worth noting that the content of BECCs was 15.0% (w/w) of
the original CP, and could be considered as the “defined
labeled amount” of active constituents for CP against MI. It
is promising that this screening method has a great potential in
promoting standardization of herbal medicines. There are
other possible applications of this method, for example in
the assessment of toxic compounds or the analysis of integra-
tive mechanisms of unrefined mixtures. The successful identi-
fication of naturally existing and integrative BECCs from the
original efficacious formula leads us to suggest that our screen-
ing method could be used for multicomponent-based drug
design (40,41).
CONCLUSION
In conclusion, using the bioactive equivalence oriented feed-
back screening method, a combination of 18 compounds was
identified as BECCs from Cardiotonic Pill (CP), which ac-
counts for 15.0% (w/w) of original CP. We have demonstrat-
ed that the BECCs were as effective as CP in cell culture
experiments and in a rat model of MI. Our future studies will
focus on optimization of the BECCs and the elucidation of
their multiple targets and possible synergistic mechanisms.
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